Henry James International Management Inc. Sells 3,608 Shares of Novo Nordisk A/S (NYSE:NVO)

Henry James International Management Inc. trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.5% in the third quarter, HoldingsChannel.com reports. The fund owned 52,156 shares of the company’s stock after selling 3,608 shares during the quarter. Novo Nordisk A/S comprises about 2.2% of Henry James International Management Inc.’s investment portfolio, making the stock its 13th biggest position. Henry James International Management Inc.’s holdings in Novo Nordisk A/S were worth $6,210,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Ground Swell Capital LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $377,000. Forum Financial Management LP raised its holdings in shares of Novo Nordisk A/S by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 23,678 shares of the company’s stock worth $2,819,000 after buying an additional 257 shares in the last quarter. BSW Wealth Partners raised its holdings in shares of Novo Nordisk A/S by 4.2% during the 3rd quarter. BSW Wealth Partners now owns 9,083 shares of the company’s stock worth $1,082,000 after buying an additional 369 shares in the last quarter. Nvwm LLC raised its holdings in shares of Novo Nordisk A/S by 1.1% during the 3rd quarter. Nvwm LLC now owns 11,795 shares of the company’s stock worth $1,404,000 after buying an additional 131 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Novo Nordisk A/S by 15.1% during the 3rd quarter. Van ECK Associates Corp now owns 492,467 shares of the company’s stock worth $56,998,000 after buying an additional 64,635 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $109.93 on Monday. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The business has a 50-day simple moving average of $124.25 and a two-hundred day simple moving average of $130.94. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The stock has a market cap of $493.31 billion, a PE ratio of 38.34, a PEG ratio of 1.46 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The firm had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.66%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.